Printer Friendly

CRYOMEDICAL SCIENCES ANNOUNCES SHIPMENT OF CMS ACCUPROBE SYSTEMS

CRYOMEDICAL SCIENCES ANNOUNCES SHIPMENT OF CMS ACCUPROBE SYSTEMS
 ROCKVILLE, Md., June 30 /PRNewswire/ -- Cryomedical Sciences, Inc. (NASDAQ: CMSI), announced today the first commercial shipment of its CMS AccuProbe System, a cryosurgical device used for the treatment of liver cancer and for minimally invasive treatment of prostate cancer.
 The CMS AccuProbe is being shipped today to Allegheny General Hospital in Pittsburgh, where a prototype system has been in use since last October. On July 10, the company plans to ship its second device to The University of Texas M.D. Anderson Cancer Center in Houston and expects to continue regular monthly shipments throughout fiscal 1993 which begins on July 1, 1992. Additional delivery sites will be announced as appropriate.
 The base price for the CMS AccuProbe System is $150,000 and disposable probes are $300 each. Once a system is installed and in service, the company believes each one will utilize between 500 and 1,000 disposable probes annually. While it is difficult to predict the scope of market acceptance of a new medical product in its first year roll-out, it is the company's goal to deliver between 25 and 35 systems over the next 12 months. The company estimates that if 30 systems are placed in the field during this period, revenues of approximately $5 million to $7 million could be attained during fiscal 1993 from the sales of the devices and disposable probes.
 According to J.J. Finkelstein, president and CEO: "We are obviously excited about shipping the first CMS AccuProbe today and officially entering the commercial market. To that end, we have invested considerable time in setting up manufacturing and support facilities to accommodate anticipated sales and to prepare for future growth." According to the company, there are approximately 3,500 hospitals in the United States that are being targeted as potential purchasers of the device.
 To date over 100 patients have been treated using the CMS AccuProbe System, including 75 prostate cancer patients and 25 liver cancer patients, among others. The company is continuing to vigorously explore other conditions in which minimally invasive cryosurgery might be of significant benefit and will soon participate in clinical studies for the treatment of BPH (enlarged prostate).
 The CMS AccuProbe utilizes extreme cold (approximately -190 degrees Celsius) to treat cancerous tumors of the prostate, liver and other organs. The destroyed tissue is left in situ (in place) and is absorbed by the body over a period of time. The procedure has several advantages over traditional surgical procedures since, in many cases, it allows the use of minimal surgical intervention; results in reduced blood loss; provides more targeted treatment, thus sparing healthy tissue; uses disposable probes to increase reliability and safety; and has the potential to substantially reduce hospital costs. To date, the company has received worldwide patents on the CMS AccuProbe and several other patents are pending.
 CMS received 510(k) pre-market clearance from the Food and Drug Administration for the AccuProbe System in April 1991 and last October announced its first use in patients with cancer of the prostate and liver. In March 1992 the company announced that medical centers in the United States and England and a U.S. medical distributor had placed orders for 10 systems, several of which were placed under the company's luminary accounts program.
 Cryomedical Sciences, Inc., is a biomedical firm engaged in the development of products in the field of hypothermic (low temperature) medicine.
 -0- 6/30/92
 /NOTE: CMS AccuProbe is a trademark./
 /CONTACT: J.J. Finkelstein of Cryomedical Sciences, 301-417-7070/
 (CMSI) CO: Cryomedical Sciences, Inc. ST: Maryland IN: MTC SU:


DC -- DC018 -- 5220 06/30/92 13:40 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 30, 1992
Words:607
Previous Article:BROCK EXPLORATION CONTINUES TO REPORT POSITIVE EARNINGS
Next Article:EQUIFAX AND EIGHTEEN STATES SIGN AGREEMENT OF ASSURANCES
Topics:


Related Articles
CRYOMEDICAL SCIENCES' ACCUPROBE IS USED SUCCESSFULLY IN PROSTATE SURGERY AT UNIVERSITY OF TEXAS CANCER CENTER
CRYOMEDICAL SCIENCES ADDS ROBERT SCHOELLHORN, FORMER CEO AND CHAIRMAN OF ABBOTT LABORATORIES, TO BOARD OF DIRECTORS
NEW METHOD TO TREAT PROSTATE CANCER SHOWS PROMISE AT ALLEGHENY GENERAL HOSPITAL
TWO NEW STUDIES SUPPORT CRYOSURGERY AS A MINIMALLY INVASIVE SURGICAL TOOL FOR PROSTATE CANCER
CRYOMEDICAL SCIENCES ANNOUNCES FISCAL YEAR 1993 BUSINESS AND FINANCIAL RESULTS; 35 CMS ACCUPROBE SYSTEMS SOLD; ORDER BACKLOG TOPS $10 MILLION
CRYOMEDICAL SCIENCES, INC. ANNOUNCES EUROPEAN DISTRIBUTION AGREEMENT WITH B&K MEDICAL A/S
CRYOMEDICAL SCIENCES ANNOUNCES FIRST QUARTER FISCAL YEAR 1995 BUSINESS AND FINANCIAL RESULTS
CRYOMEDICAL SCIENCES ADDS HENRY PIETRASZEK TO BOARD OF DIRECTORS
CRYOMEDICAL SCIENCES INC. NETS $1.91 MILLION EQUITY INVESTMENT
Court Finds No Trade Secrets Imparted in CMSI vs. ENDOcare

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters